MetaVia Inc. (MTVA)
| Market Cap | 5.73M -13.1% |
| Revenue (ttm) | n/a |
| Net Income | -13.13M |
| EPS | -4.79 |
| Shares Out | 5.16M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 36,139 |
| Open | 1.170 |
| Previous Close | 1.190 |
| Day's Range | 1.110 - 1.197 |
| 52-Week Range | 0.966 - 19.029 |
| Beta | 0.58 |
| Analysts | Strong Buy |
| Price Target | 26.50 (+2,287.39%) |
| Earnings Date | May 14, 2026 |
About MTVA
MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 rece... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for MTVA stock is "Strong Buy." The 12-month stock price target is $26.5, which is an increase of 2,287.39% from the latest price.
News
MetaVia Reports First Quarter 2026 Financial Results and Provides Corporate Update
48 mg Phase 1 Data Demonstrated Potential Best-in-Class Profile for DA-1726 with 9.1% Weight Loss, Improved Glucose Control and Direct Liver Benefit Key Milestone Achieved with Dosing of the First Pat...
MetaVia to Present Data Highlighting DA-1726, a GLP-1/Glucagon Dual Agonist, in a Late-Breaking Poster Presentation at the EASL Congress 2026
CAMBRIDGE, Mass., May 11, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that a late-breakin...
MetaVia says first patient dosed in Part 3 of Phase 1 trial of DA-1726
MetaVia (MTVA) announced that the first patient has been dosed in Part 3 of its Phase 1 clinical trial evaluating DA-1726, a novel dual oxyntomodulin analog targeting both GLP-1 and…
MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity
16-Week Study Evaluates One-Step Dose Titration to 48 mg and Two-Step Dose Titration to 64 mg in Obese Otherwise Healthy Adults CAMBRIDGE, Mass., April 10, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: M...
MetaVia: Cash position adequate to fund operations into 4Q26
Cash and cash equivalents were $10.3M as of December 31, 2025, compared with $16M as of December 31, 2024. With these funds and proceeds from the January 2026 public offering,…
MetaVia CEO says ‘significant progress advancing our cardiometabolic portfolio’
“We made significant progress advancing our cardiometabolic portfolio during the year, punctuated by the positive data, released in January of this year, from the Phase 1 extended 8-week, non-titrated...
MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update
48 mg Phase 1 Data Demonstrate Potential Best-in-Class Profile for DA-1726 with 9.1% Weight Loss, Improved Glucose Control and Direct Liver Benefit Planned Phase 1 Part 3 16-Week Titration Study to Ev...
MetaVia announces IRB at Clinical Pharmacology of Miami approved Phase 1 study
MetaVia (MTVA) announced that the Institutional Review Board, IRB, at Clinical Pharmacology of Miami has approved the Company’s Phase 1 Part 3 clinical trial of its lead asset, DA-1726, a…
MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control
16-Week Study to Evaluate One-Step Dose Titration to 48 mg and Two-Step Dose Titration to 64 mg in Obese Otherwise Healthy Adults CAMBRIDGE, Mass., March 18, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq:...
MetaVia Transcript: Life Sciences Virtual Investor Forum
DA-1726, a dual GLP-1/glucagon agonist, shows rapid and significant weight and waist reduction with promising metabolic and liver benefits. Upcoming trials aim for higher efficacy and improved tolerability, with key data expected before year-end.
MetaVia expands global patent protection for vanoglipel into 2035
MetaVia (MTVA) announced a comprehensive global intellectual property portfolio supporting vanoglipel, its novel, orally available G-protein-coupled receptor 119 agonist. This currently includes 48 gr...
MetaVia Expands Global Patent Protection for Vanoglipel, Supporting Metabolic and Liver Disease Therapy Through 2035
Patent Portfolio Includes 48 Granted and Pending Patents in the U.S., Europe, Japan, China and other Countries, Providing Protection Into 2035, Unless Extended Further CAMBRIDGE, Mass., March 12, 2026...
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum
CAMBRIDGE, Mass., March 4, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Ki...
MetaVia Transcript: Emerging Growth Virtual Conference
Significant progress was reported for two cardiometabolic assets, with DA-1726 showing strong early efficacy in obesity and vanoglipel meeting endpoints in MASH. Upcoming data releases and ongoing phase I titration studies are expected to drive value, supported by a solid cash position and active partnership discussions.
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference
CAMBRIDGE, Mass., Feb. 17, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Ki...
MetaVia Builds Comprehensive Global Patent Protection for DA-1726, Securing Exclusive Rights to Novel Obesity and Metabolic Therapy Through 2041
Intellectual Property Portfolio Includes 39 Granted and Pending Patents in the U.S. and Internationally, Providing Protection Into 2041, Unless Extended Further CAMBRIDGE, Mass., Feb. 13, 2026 /PRNews...
MetaVia Announces Positive AI-Modeling Results from its Ongoing Syntekabio Collaboration, Confirming Key Therapeutic Targets for Vanoglipel
DeepMatcher® Platform Confirms Strong Inflammatory and Cardiometabolic Target Engagement, Supporting Development in MASH and Potential Type 2 Diabetes CAMBRIDGE, Mass., Feb. 4, 2026 /PRNewswire/ -- Me...
MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option
CAMBRIDGE, Mass., Jan. 16, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA) (MetaVia or the Company), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today ann...
MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering
CAMBRIDGE, Mass., Jan. 15, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA) (MetaVia or the Company), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today ann...
MetaVia Reports Positive Statistically Significant Results from Its Phase 1b Clinical Trial of DA-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss and Favorable Safety Profile
Statistically Significant (p=0.006) Waist Circumference Reduction of 9.8 cm at Day 54 Significant Direct Hepatic Activity with a 23.7% Reduction in Liver Stiffness (VCTE) by Day 54 Strong Glycemic Res...
MetaVia to Participate in and Sponsor the 10th Annual MASH-TAG 2026 Conference
CAMBRIDGE, Mass. , Dec. 29, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it will part...
MetaVia Regains Compliance with Nasdaq Minimum Bid Price Requirement
CAMBRIDGE, Mass. , Dec. 22, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that on December ...
MetaVia Inc. Announces 1-for-11 Reverse Stock Split
CAMBRIDGE, Mass. , Dec. 2, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA) ("MetaVia" or the "Company"), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today...
MetaVia Presents Positive New Phase 2a Data on Vanoglipel (DA-1241) in Patients with Presumed MASH at the AASLD The Liver Meeting® 2025
Oral GPR119 Agonist Demonstrated Clinically Meaningful Reductions in HbA1c, Improvements in Liver Inflammation and Fibrosis, and Favorable Changes in Plasma Lipidomic Profiles CAMBRIDGE, Mass. , Nov. ...
MetaVia Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Dosed the First Patient in the 8-Week 48 mg MAD Cohort of its Phase 1 Clinical Trial to Further Explore Non-Titrated Maximum Tolerated Dose of DA-1726 for the Treatment of Obesity; Top-Line Data Expec...